Resisting CAR T-cell Therapy: A Case Study.
A case report highlights a novel, rare mechanism of resistance to chimeric antigen receptor (CAR) T-cell therapy, conferred by the accidental transduction of a single leukemic B cell with the anti-CD19 CAR (CAR19) gene during therapy manufacturing. Because CAR19 bound directly to CD19 on the cell surface-a phenomenon called in cis epitope masking-the therapeutic target was effectively hidden from reprogrammed T cells.